BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33719177)

  • 1. Cytosolic Delivery of Thiolated Mn-cGAMP Nanovaccine to Enhance the Antitumor Immune Responses.
    Chen C; Tong Y; Zheng Y; Shi Y; Chen Z; Li J; Liu X; Zhang D; Yang H
    Small; 2021 Apr; 17(17):e2006970. PubMed ID: 33719177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
    Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
    Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
    Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
    JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response.
    Li T; Cheng H; Yuan H; Xu Q; Shu C; Zhang Y; Xu P; Tan J; Rui Y; Li P; Tan X
    Sci Rep; 2016 Jan; 6():19049. PubMed ID: 26754564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
    Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
    J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
    Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
    Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer.
    Da Y; Liu Y; Hu Y; Liu W; Ma J; Lu N; Zhang C; Zhang C
    Oncoimmunology; 2022; 11(1):2054105. PubMed ID: 35371622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis and Biological Evaluation of (2',5' and 3'5'-Linked) cGAMP Analogs that Activate Stimulator of Interferon Genes (STING).
    Xie X; Liu J; Wang X
    Molecules; 2020 Nov; 25(22):. PubMed ID: 33198423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the cGAS-cGAMP-STING Activity of Cancer Cells.
    Pépin G; Gantier MP
    Methods Mol Biol; 2018; 1725():257-266. PubMed ID: 29322423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LL-37 transports immunoreactive cGAMP to activate STING signaling and enhance interferon-mediated host antiviral immunity.
    Wei X; Zhang L; Yang Y; Hou Y; Xu Y; Wang Z; Su H; Han F; Han J; Liu P; Hu S; Koci MD; Sun X; Zhang C
    Cell Rep; 2022 May; 39(9):110880. PubMed ID: 35649354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cGAS is essential for the antitumor effect of immune checkpoint blockade.
    Wang H; Hu S; Chen X; Shi H; Chen C; Sun L; Chen ZJ
    Proc Natl Acad Sci U S A; 2017 Feb; 114(7):1637-1642. PubMed ID: 28137885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma.
    Li K; Ye Y; Liu L; Sha Q; Wang X; Jiao T; Zhang L; Wang J
    Biomater Sci; 2021 Feb; 9(3):765-773. PubMed ID: 33201161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination.
    Junkins RD; Gallovic MD; Johnson BM; Collier MA; Watkins-Schulz R; Cheng N; David CN; McGee CE; Sempowski GD; Shterev I; McKinnon K; Bachelder EM; Ainslie KM; Ting JP
    J Control Release; 2018 Jan; 270():1-13. PubMed ID: 29170142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lanthanide-Nucleotide Coordination Nanoparticles for STING Activation.
    Luo Z; Liang X; He T; Qin X; Li X; Li Y; Li L; Loh XJ; Gong C; Liu X
    J Am Chem Soc; 2022 Sep; 144(36):16366-16377. PubMed ID: 36037283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy.
    Lu ZD; Chen YF; Shen S; Xu CF; Wang J
    ACS Appl Mater Interfaces; 2021 Jun; 13(25):29424-29438. PubMed ID: 34129318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of doxorubicin and STING agonist cGAMP for enhanced antitumor immunity.
    Xie Y; Li K; Liang J; Wang K; Gong Z; Chen X
    Int J Pharm; 2024 Apr; 654():123955. PubMed ID: 38423155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy.
    Luo T; Nash GT; Jiang X; Feng X; Mao J; Liu J; Juloori A; Pearson AT; Lin W
    Adv Mater; 2022 Sep; 34(39):e2110588. PubMed ID: 35952624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An alternatively spliced STING isoform localizes in the cytoplasmic membrane and directly senses extracellular cGAMP.
    Li X; Zhu Y; Zhang X; An X; Weng M; Shi J; Wang S; Liu C; Luo S; Zheng T
    J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 34905508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
    Deng L; Liang H; Xu M; Yang X; Burnette B; Arina A; Li XD; Mauceri H; Beckett M; Darga T; Huang X; Gajewski TF; Chen ZJ; Fu YX; Weichselbaum RR
    Immunity; 2014 Nov; 41(5):843-52. PubMed ID: 25517616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.